Health Care & Life Sciences » Biotechnology | Achillion Pharmaceuticals Inc.

Achillion Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Achillion Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
SPDR S&P Biotech ETF
3,887,284
2.81%
10,002
0.23%
09/06/2018
Vanguard Total Stock Market Index Fund
3,572,846
2.58%
368,300
0%
07/31/2018
Vanguard Small Cap Index Fund
3,308,877
2.39%
56,602
0.01%
07/31/2018
iShares Russell 2000 ETF
2,953,585
2.13%
-1,578
0.02%
09/06/2018
Vanguard Small Cap Growth Index Fund
1,874,826
1.35%
20,168
0.03%
07/31/2018
Vanguard Extended Market Index Fund
1,843,718
1.33%
0
0.01%
07/31/2018
iShares Nasdaq Biotechnology ETF
1,591,757
1.14%
-20,811
0.06%
09/06/2018
Biotech Growth Trust Plc (The)
1,420,834
1.02%
-1,293
0.71%
09/30/2017
DFA US Small Cap Portfolio
1,296,703
0.94%
294,591
0.02%
04/30/2018
BB Biotech AG
1,279,340
0.92%
0
0.11%
03/31/2018

About Achillion Pharmaceuticals

View Profile
Address
VEVA Building 14
Blue Bell Pennsylvania 19422
United States
Employees -
Website http://www.achillion.com
Updated 07/08/2019
Achillion Pharmaceuticals, Inc. engages in the discovery and development of small molecule drug therapies for immune system disorders. It offers its propriety platform of potent and specific complement factor D inhibitors for AP-mediated diseases. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.